tetano
Editor, Senior Moderator
J Inflamm Res
. 2021 Feb 2;14:245-251.
doi: 10.2147/JIR.S290264. eCollection 2021.
Neopterin: A Promising Candidate Biomarker for Severe COVID-19
Wasihun Hailemichael[SUP] 1 [/SUP], Mulugeta Kiros[SUP] 2 [/SUP], Yibeltal Akelew[SUP] 3 [/SUP], Sisay Getu[SUP] 4 [/SUP], Henok Andualem[SUP] 1 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has rapidly spread across the world since its first emergence in China in late 2019. It is a major public health concern with no effective treatct 3ments. The immunopathology of SARS-CoV-2 is associated with an excessive inflammatory response. Macrophage activation syndrome (MAS) is also associated with the severity of the disease in SARS-CoV-2-infected patients. Neopterin is a macrophage activation marker produced by monocytes and macrophages upon activation by interferon-gamma (IFN-γ). Neopterin is a well-established marker in a variety of diseases, and recent evidence indicates that it could be helpful in early prediction of the severity of COVID-19 disease and serve as a prognostic marker. Here, we outline the role of macrophage activation syndrome in the pathogenesis of SARS-CoV-2 and suggest that neopterin could be used as a biomarker for progression of COVID-19.
Keywords: COVID-19; MAS; SARS-CoV-2; biomarker; neopterin.
. 2021 Feb 2;14:245-251.
doi: 10.2147/JIR.S290264. eCollection 2021.
Neopterin: A Promising Candidate Biomarker for Severe COVID-19
Wasihun Hailemichael[SUP] 1 [/SUP], Mulugeta Kiros[SUP] 2 [/SUP], Yibeltal Akelew[SUP] 3 [/SUP], Sisay Getu[SUP] 4 [/SUP], Henok Andualem[SUP] 1 [/SUP]
Affiliations
- PMID: 33564258
- PMCID: PMC7866915
- DOI: 10.2147/JIR.S290264
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has rapidly spread across the world since its first emergence in China in late 2019. It is a major public health concern with no effective treatct 3ments. The immunopathology of SARS-CoV-2 is associated with an excessive inflammatory response. Macrophage activation syndrome (MAS) is also associated with the severity of the disease in SARS-CoV-2-infected patients. Neopterin is a macrophage activation marker produced by monocytes and macrophages upon activation by interferon-gamma (IFN-γ). Neopterin is a well-established marker in a variety of diseases, and recent evidence indicates that it could be helpful in early prediction of the severity of COVID-19 disease and serve as a prognostic marker. Here, we outline the role of macrophage activation syndrome in the pathogenesis of SARS-CoV-2 and suggest that neopterin could be used as a biomarker for progression of COVID-19.
Keywords: COVID-19; MAS; SARS-CoV-2; biomarker; neopterin.